keyword
MENU ▼
Read by QxMD icon Read
search

Dementia diagnosis

keyword
https://www.readbyqxmd.com/read/28527211/alzheimer-s-disease-in-the-latino-community-intersection-of-genetics-and-social-determinants-of-health
#1
Irving E Vega, Laura Y Cabrera, Cassandra M Wygant, Daniel Velez-Ortiz, Scott E Counts
Alzheimer's disease (AD) is the most common type of dementia among individuals 65 or older. There are more than 5 million diagnosed cases in the US alone and this number is expected to triple by 2050. Therefore, AD has reached epidemic proportions with significant socioeconomic implications. While aging in general is the greatest risk factor for AD, several additional demographic factors that have contributed to the rise in AD in the US are under study. One such factor is associated with the relatively fast growth of the Latino population...
May 17, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28527210/cerebrospinal-fluid-biomarkers-and-clinical-progression-in-patients-with-subjective-cognitive-decline-and-mild-cognitive-impairment
#2
Steffen Wolfsgruber, Alexandra Polcher, Alexander Koppara, Luca Kleineidam, Lutz Frölich, Oliver Peters, Michael Hüll, Eckart Rüther, Jens Wiltfang, Wolfgang Maier, Johannes Kornhuber, Piotr Lewczuk, Frank Jessen, Michael Wagner
BACKGROUND: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD). OBJECTIVE: To assess the frequency of abnormal CSF biomarkers of AD and their predictive value for clinical progression in memory clinic patients with SCD in comparison to patients with mild cognitive impairment (MCI) from the same cohort...
May 13, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28527206/social-representation-of-dementia-an-analysis-of-5-792-consecutive-cases-evaluated-in-a-memory-clinic
#3
Pilar Cañabate, Gabriel Martínez, Maitée Rosende-Roca, Mariola Moreno, Silvia Preckler, Sergi Valero, Oscar Sotolongo, Isabel Hernández, Montserrat Alegret, Gemma Ortega, Ana Espinosa, Ana Mauleón, Liliana Vargas, Octavio Rodríguez, Carla Abdelnour, Domingo Sánchez, Elvira Martín, Agustín Ruiz, Lluís Tárraga, Mercè Boada
BACKGROUND: Different interpretations of cognitive impairment and dementia due to differences in health structures, such as cultural differences could affect the diagnosis and treatment of the condition. it is reasonable to expect that the social and family impact of the disease and coping strategies will differ among societies. OBJECTIVE: The general aim of this study is to understand the social representations of dementia, its associated practices, and the effects they imply...
May 17, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28525567/saccadic-eye-movements-and-attentional-control-in-alzheimer-s-disease
#4
Nicolas Noiret, Nicolas Carvalho, Éric Laurent, Gilles Chopard, Mickaël Binetruy, Magali Nicolier, Julie Monnin, Eloi Magnin, Pierre Vandel
Objective: Several studies have demonstrated saccadic eye movement (SEM) abnormalities in Alzheimer's disease (AD) when patients performed prosaccade (PS) and antisaccade (AS) tasks. Some studies have also showed that SEM abnormalities were correlated with dementia rating tests such as the Mini Mental State Evaluation (MMSE). Therefore, it has been suggested that SEMs could provide useful information for diagnosis. However, little is known about predictive saccades (PreS)-saccades triggered before or very quickly after stimuli appearance-and their relationships with cognition in AD...
May 19, 2017: Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists
https://www.readbyqxmd.com/read/28515553/long-loop-reflex-2-in-patients-with-cortical-dementias-a-pilot-study
#5
Sadanandavalli Retnaswami Chandra, Thomas Gregor Isaac, Mahesh Mane, Srikala Bharath, B C Nagaraju
INTRODUCTION: Dementia is a major public health problem and it appears to be a global epidemic. The prevalence is doubling every 5 years and it is expected that 70% of persons above 60 years will live in developing countries by 2020 and 15% of them are likely to suffer from dementia. Disease modifying treatments work only if initiated very early; however, diagnostic tools are not always able to clearly differentiate the different types in very early stage. Therefore, inexpensive and easily available biomarkers are needed to know if collectively they will improve the sensitivity of specific diagnosis...
March 2017: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/28514961/how-many-people-will-need-palliative-care-in-2040-past-trends-future-projections-and-implications-for-services
#6
S N Etkind, A E Bone, B Gomes, N Lovell, C J Evans, I J Higginson, F E M Murtagh
BACKGROUND: Current estimates suggest that approximately 75% of people approaching the end-of-life may benefit from palliative care. The growing numbers of older people and increasing prevalence of chronic illness in many countries mean that more people may benefit from palliative care in the future, but this has not been quantified. The present study aims to estimate future population palliative care need in two high-income countries. METHODS: We used mortality statistics for England and Wales from 2006 to 2014...
May 18, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28514478/trajectories-of-depressive-symptoms-before-diagnosis-of-dementia-a-28-year-follow-up-study
#7
Archana Singh-Manoux, Aline Dugravot, Agnes Fournier, Jessica Abell, Klaus Ebmeier, Mika Kivimäki, Séverine Sabia
Importance: Neuropsychiatric symptoms, depressive symptoms in particular, are common in patients with dementia but whether depressive symptoms in adulthood increases the risk for dementia remains the subject of debate. Objective: To characterize the trajectory of depressive symptoms over 28 years prior to dementia diagnosis to determine whether depressive symptoms carry risk for dementia. Design, Setting, and Participants: Up to 10 308 persons, aged 35 to 55 years, were recruited to the Whitehall II cohort study in 1985, with the end of follow-up in 2015...
May 17, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28509347/domain-specific-cognitive-impairment-in-non-demented-parkinson-s-disease-psychosis
#8
Jared T Hinkle, Kate Perepezko, Catherine C Bakker, Ted M Dawson, Vanessa Johnson, Zoltan Mari, Cherie L Marvel, Kelly A Mills, Alexander Pantelyat, Olga Pletnikova, Liana S Rosenthal, Melissa D Shepard, Daniel A Stevens, Juan C Troncoso, Jiangxia Wang, Gregory M Pontone
INTRODUCTION: In Parkinson's disease (PD), psychosis is associated with cognitive impairment that may be more profound in particular cognitive domains. Our goal was to determine whether psychosis in non-demented PD participants is associated with domain-specific cognitive impairment on the Mini-Mental State Exam (MMSE). METHODS: The Morris K. Udall Parkinson's Disease Research Center of Excellence Longitudinal Study at Johns Hopkins is a prospective study that was initiated in 1998...
May 16, 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28509083/detection-of-csf-14-3-3-protein-in-sporadic-creutzfeldt-jakob-disease-patients-using-a-new-automated-capillary-western-assay
#9
A Fourier, A Dorey, A Perret-Liaudet, I Quadrio
Sporadic Creutzfeldt-Jakob disease (sCJD) is a fatal rapidly progressive dementia. The detection of 14-3-3 protein in cerebrospinal fluid (CSF) is included in the WHO diagnostic criteria for the pre-mortem diagnosis of CJD. The aim of this study is to assess CSF 14-3-3 protein analytical and diagnostic performances using a new automated capillary Western technology (Simple Western technology-SW). For the validation of this assay, samples from a cohort of 268 patients suspected from sCJD were analyzed: 77 sCJD (including 40 definite sCJD) and 191 non-CJD samples were tested using both SW and the current Western Blot (WB) assays...
May 16, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28508250/a-real-world-analysis-of-treatment-patterns-for-cholinesterase-inhibitors-and-memantine-among-newly-diagnosed-alzheimer-s-disease-patients
#10
Nawal Bent-Ennakhil, Florence Coste, Lin Xie, Myrlene Sanon Aigbogun, Yuexi Wang, Furaha Kariburyo, Ann Hartry, Onur Baser, Peter Neumann, Howard Fillit
INTRODUCTION: Alzheimer's disease (AD) is the most common neurodegenerative form of dementia. Pharmacological therapies for symptomatic treatment, such as acetylcholinesterase inhibitors (AChEIs) and memantine, have been available in the USA since 2000. Over the past decade, few studies have analyzed real-world anti-dementia treatment patterns in the USA. This study evaluated monotherapy AChEIs and memantine treatment patterns among newly diagnosed AD patients. METHODS: A retrospective cohort study was conducted using Medicare data and the Minimum Data Set from 2008 to 2012...
May 15, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28507532/spectral-domain-optical-coherence-tomography-as-a-new-diagnostic-marker-for-idiopathic-normal-pressure-hydrocephalus
#11
Joana M Afonso, Manuel Falcão, Frank Schlichtenbrede, Fernando Falcão-Reis, Sérgio Estrela Silva, Till M Schneider
PURPOSE: Characterized by a progressive onset of gait disturbances, dementia, and urinary incontinence, idiopathic normal pressure hydrocephalus (iNPH) is considered a rare, but under-diagnosed disease. Non-invasive diagnostic markers are still insufficient to enable the diagnosis of iNPH with certainty and yet early treatment with ventriculoperitoneal (VP) shunting can reverse symptoms and stop disease progression. Vascular circulation abnormalities in iNPH may be reflected by changes in subfoveal and peripapillary choroidal thickness (PPChT)...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28505978/an-arabic-version-of-the-cognitive-subscale-of-the-alzheimer-s-disease-assessment-scale-adas-cog-reliability-validity-and-normative-data
#12
Sonia Ben Jemaa, Neila Attia Romdhane, Amel Bahri-Mrabet, Adel Jendli, Didier Le Gall, Tarek Bellaj
The Alzheimer's Disease Assessment Scale's cognitive subscale (ADAS-Cog) is the most widely used instrument for screening cognitive dysfunction in Alzheimer's disease. The aim of the present study was to develop an Arabic version of this scale (A-ADAS-Cog), examine its psychometric properties (reliability and validity), and provide normative data. The A-ADAS-Cog), an Arabic version of the Mini-Mental State Examination (A-MMSE), and a Standardized Clinical Dementia Rating Scale (CDR) were administered to three Tunisian groups: 124 normal controls (NC), 33 patients with non-Alzheimer dementia (N-AD), and 25 patients with Alzheimer's disease (AD)...
May 11, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28505261/survival-and-causes-of-death-among-people-with-clinically-diagnosed-synucleinopathies-with-parkinsonism-a-population-based-study
#13
Rodolfo Savica, Brandon R Grossardt, James H Bower, J Eric Ahlskog, Bradley F Boeve, Jonathan Graff-Radford, Walter A Rocca, Michelle M Mielke
Importance: To our knowledge, a comprehensive study of the survival and causes of death of persons with synucleinopathies compared with the general population has not been conducted. Understanding the long-term outcomes of these conditions may inform patients and caregivers of the expected disease duration and may help with care planning. Objective: To compare survival rates and causes of death among patients with incident, clinically diagnosed synucleinopathies and age- and sex-matched referent participants...
May 15, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28504037/plasma-butyrylcholinesterase-activity-a-possible-biomarker-for-differential-diagnosis-between-alzheimer-s-disease-and-dementia-with-lewy-bodies
#14
N D Josviak, M S Batistela, R K M Souza, N R Wegner, G F Bono, C D Sulzbach, D P Simão-Silva, M R Piovezan, R L R Souza, L Furtado-Alle
Butyrylcholinesterase (BChE) is an enzyme encoded by BCHE gene, responsible for catalyzing the hydrolysis of acetylcholine. K and -116A BCHE variants were associated with decrease in plasma BChE activity, and their influence has been investigated in diseases with a cholinergic deficit such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). In order to check the influence of BCHE genetic variants on enzymatic activity, all patients and controls were genotyped for K and -116A variants. We found lower plasma BChE activity in DLB patients compared to elderly controls and to AD independent of the presence of K or -116A variants...
May 15, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/28501823/cerebellar-atrophy-in-neurodegeneration-a-meta-analysis
#15
REVIEW
Helena M Gellersen, Christine C Guo, Claire O'Callaghan, Rachel H Tan, Saber Sami, Michael Hornberger
INTRODUCTION: The cerebellum has strong cortical and subcortical connectivity, but is rarely taken into account for clinical diagnosis in many neurodegenerative conditions, particularly in the absence of clinical ataxia. The current meta-analysis aims to assess patterns of cerebellar grey matter atrophy in seven neurodegenerative conditions (Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), progressive supranuclear palsy (MSP))...
May 13, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28501143/do-we-know-how-to-diagnose-epilepsy-early-in-alzheimer-s-disease
#16
REVIEW
B Cretin, N Philippi, O Bousiges, L Dibitonto, F Sellal, C Martin-Hunyadi, F Blanc
Epilepsy is an increasingly recognized comorbidity in Alzheimer's disease (AD). First described as generalized in dementia patients, epileptic AD patients are nowadays fully described in earlier stages of the disease (with mild or subjective cognitive impairment). At such early stages, patients may present not only with generalized seizures, but also with focal seizures (commonly localized in the frontal or temporal lobe). Thus, partial or generalized epilepsy is part of the semiological spectrum of AD that should be borne in mind at all stages of disease to ensure early identification and prevent the risk of repeated seizures (such as accidents, injury, progression of cognitive impairment)...
May 10, 2017: Revue Neurologique
https://www.readbyqxmd.com/read/28501048/systematic-review-of-evidence-underpinning-non-pharmacological-therapies-in-dementia
#17
Richard Olley, Andrea Morales
Objective Dementia is one of the most common illnesses worldwide, and is one of the most important causes of disability in older people. Currently, dementia affects over 35million people around the globe. It is expected that this number will increase to 65.7million by 2030. Early detection, diagnosis and treatment to control the principal behaviour symptoms may help reduce these numbers and delay the progression to more advanced and dangerous stages of this disorder with resultant increase quality of life for those affected...
May 15, 2017: Australian Health Review: a Publication of the Australian Hospital Association
https://www.readbyqxmd.com/read/28500752/which-ante-mortem-clinical-features-predict-progressive-supranuclear-palsy-pathology
#18
Gesine Respondek, Carolin Kurz, Thomas Arzberger, Yaroslau Compta, Elisabet Englund, Leslie W Ferguson, Ellen Gelpi, Armin Giese, David J Irwin, Wassilios G Meissner, Christer Nilsson, Alexander Pantelyat, Alex Rajput, John C van Swieten, Claire Troakes, Keith A Josephs, Anthony E Lang, Brit Mollenhauer, Ulrich Müller, Jennifer L Whitwell, Angelo Antonini, Kailash P Bhatia, Yvette Bordelon, Jean-Christophe Corvol, Carlo Colosimo, Richard Dodel, Murray Grossman, Jan Kassubek, Florian Krismer, Johannes Levin, Stefan Lorenzl, Huw Morris, Peter Nestor, Wolfgang H Oertel, Gil D Rabinovici, James B Rowe, Thilo van Eimeren, Gregor K Wenning, Adam Boxer, Lawrence I Golbe, Irene Litvan, Maria Stamelou, Günter U Höglinger
BACKGROUND: Progressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes. OBJECTIVE: To identify clinical features and investigations that predict or exclude PSP pathology during life, aiming at an optimization of the clinical diagnostic criteria for PSP. METHODS: We performed a systematic review of the literature published since 1996 to identify clinical features and investigations that may predict or exclude PSP pathology...
May 13, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28499316/-diagnostic-and-prescription-behavior-of-general-practitioners-and-specialist-physicians-in-patients-with-dementia-in-2005-and-2015-in-germany
#19
Jens Bohlken, Karel Kostev
Research Question Did the diagnostic and treatment behavior of general practitioners and specialists in patients with dementia (PWD) change in Germany over a period of 11 years (2005 vs. 2015)? Methods We performed a retrospective, database-based evaluation of diagnostic and prescription data from more than 398 general practices (GP) and 50 specialist practices (SP). Results Compared to 2005, in 2015, the number of PWD had increased by 40.7 % in GP and by 52.4 % in SP. The proportion of patients with DAT (Alzheimer's Disease) had increased from 45...
May 12, 2017: Psychiatrische Praxis
https://www.readbyqxmd.com/read/28495476/studies-on-diagnostic-biomarkers-and-therapeutic-mechanism-of-alzheimer-s-disease-through-metabolomics-and-hippocampal-proteomics
#20
Weiwei Lin, Jianmei Zhang, Yanmeng Liu, Ruijun Wu, Haisong Yang, Xiaobo Hu, Xiaomei Ling
Alzheimer's disease (AD) is the main cause of dementia, but precise diagnosis and treatment are not sufficient so far. The purpose of this study is to develop biomarkers and therapeutic targets for diagnosis and better understanding of AD. As a result, lysophosphatidylcholine and intermediates of sphingolipid metabolism including sphinganine-1-phosphate, sphingosine-1-phosphate, sphingomyelin, and sphingosine in plasma were annotated as potential biomarkers by using UPLC-Q-TOF-MS and UHPLC-Q-Exactive-MS. Besides, glutathione S-transferases (GSTs) including GstA3, Gstm1, Gstm5, Gstm3, Gstk1 and Gstp1 were significantly enhanced in AD hippocampus by using label free nano-LC-MS/MS...
May 8, 2017: European Journal of Pharmaceutical Sciences
keyword
keyword
69714
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"